Dopamine agonists and the risk of cardiac-valve regurgitation
about
Benfluorex and unexplained valvular heart disease: a case-control studyValvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individualsCabergoline for preventing ovarian hyperstimulation syndromeCabergoline for preventing ovarian hyperstimulation syndromeTreatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.Sleep and aging: 2. Management of sleep disorders in older peopleSide effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacologyThe Treatment of Cushing's Disease.Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessmentCan dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysisParkinson's disease or Parkinson symptoms following seasonal influenza.Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach.Medical treatment of Cushing's disease: Overview and recent findings.Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink.Management of acromegaly in Latin America: expert panel recommendationsPredictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart diseaseCardiovascular medication burden in dementia disorders: a nationwide study of 19,743 dementia patients in the Swedish Dementia Registry.Performance of a semi-automated approach for risk estimation using a common data model for longitudinal healthcare databases.Diagnosis and management of restless legs syndrome in children.Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum.Drug-induced valvulopathy: an update.Serotonin receptors and heart valve disease--it was meant 2B.Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy.Anti-angiogenic treatment strategies for the therapy of endometriosis.Early prediction of long-term response to cabergoline in patients with macroprolactinomasPramipexole use and the risk of pneumoniaDopamine agonists for preventing ovarian hyperstimulation syndrome.Advances in understanding pituitary tumorsTrazodone generates m-CPP: in 2008 risks from m-CPP might outweigh benefits of trazodone.The expanded biology of serotonin.Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohortsInflammatory regulation of valvular remodeling: the good(?), the bad, and the ugly.Detecting adverse drug reactions following long-term exposure in longitudinal observational data: The exposure-adjusted self-controlled case series.Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists.Dopamine receptors and Parkinson's diseaseDopamine agonists and ischemic complications in Parkinson's disease: a nested case-control study.Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adultsDoes Twice-weekly Cabergoline Improve Anthropometrical and Biochemical Profiles in Prediabetes? A Randomized Double-blind Clinical Trial Pilot Study.Medical management of functioning pituitary adenoma: an update.
P2860
Q21091138-C3A110EF-036E-4415-A353-430223C47FCCQ21245270-940BFD6A-8F23-49F0-9999-FF2318073E1EQ24203638-BAA0F910-BC5A-4868-A916-F27FA40965BFQ24234591-4CC21CBB-AF61-4781-8245-C5EFA670A2C8Q24629410-21DEEE80-59A7-4CDF-947C-62DAA2D6ACF9Q24674548-2D81A0F9-A70B-4270-B584-70ED7E67B4B6Q26738349-6D3F5FFC-587E-48AD-9DB0-66A0C4046471Q27010590-577FA4A1-272E-47CC-99DC-63D93EB86D3BQ28250560-2158187E-3840-4B92-AFE6-BF463D19B149Q28278251-9B05893E-0B09-44FB-83A2-4FBBBAEC3CCDQ30403795-67F374BD-343F-4C33-B73B-FA955F0F331EQ33579615-E4D393DB-AFA7-4C8B-A66E-9E97BB5D6E79Q33721266-5CAE8A1B-AAD7-403C-B43E-2D99D9ADEBE4Q33735039-8359CBB9-A615-4ECC-9851-FEBEC6DFCD43Q33739454-FAFC007A-B991-4A3F-BEB7-D78D4C436FB4Q33794388-2AFC9B73-3420-494F-8633-E547E4F52C8FQ33863285-7A32D37D-CCF4-4D0B-8F06-C6F7657F8FD2Q33892785-02C233A7-396F-4C76-9384-DE088E97A9CBQ33934896-B8A85777-A2D0-4BB1-B956-9E8C68DB86B6Q34026340-8FF5D826-E97C-483D-AC4F-944884ADC8C1Q34096784-D6D1225A-C721-4BF6-A0DD-6C0CB1E8B58AQ34131760-19EA6572-C12D-4E20-961B-C10481FA6FD4Q34173511-1DE8A8F9-8580-49CD-A53B-83B512F239E2Q34256300-9C95A734-F6A7-4B84-AC90-E0EC35F0DD65Q34283036-108ECEB1-407C-4E81-B662-C2124B503530Q34318860-A829EDCA-0C65-4820-A43B-EC98DBA7D6DBQ34423774-FEF41109-CBE4-4C77-A02B-7EDB7055311CQ34546236-FF53F68A-060B-4A79-852D-EEB36F7A8D82Q34660143-282F133E-EC6C-4E12-8A59-294853944355Q34977162-FE93E81E-8871-457E-B4FB-2F08F2416FC7Q34993925-8F980AB7-0710-4C7D-AD13-808488BE4886Q35093193-9C3020F7-77C4-475E-91C0-F465C3D2D429Q35116249-BC6270F6-5C96-4FAF-B083-9CD4A5E1601AQ35135876-7F307228-8CD3-44F3-8754-6B4CEC321570Q35137687-D060976C-67A0-495D-A44D-6CEC9904F7CAQ35545020-E4B6AE31-22F5-4726-91CE-6005F69A141DQ35644029-8EE2F4A8-2451-43D7-91C4-F24428EB4B84Q35791125-EC5905C6-B6CB-4393-9479-DD8FD5D3FD52Q35843293-14595044-146F-46A3-AC70-7D1933F110A7Q35943493-617327BF-4B23-4359-AB9E-89C4A852EB22
P2860
Dopamine agonists and the risk of cardiac-valve regurgitation
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Dopamine agonists and the risk of cardiac-valve regurgitation
@ast
Dopamine agonists and the risk of cardiac-valve regurgitation
@en
Dopamine agonists and the risk of cardiac-valve regurgitation
@nl
type
label
Dopamine agonists and the risk of cardiac-valve regurgitation
@ast
Dopamine agonists and the risk of cardiac-valve regurgitation
@en
Dopamine agonists and the risk of cardiac-valve regurgitation
@nl
prefLabel
Dopamine agonists and the risk of cardiac-valve regurgitation
@ast
Dopamine agonists and the risk of cardiac-valve regurgitation
@en
Dopamine agonists and the risk of cardiac-valve regurgitation
@nl
P2093
P3181
P356
P1476
Dopamine agonists and the risk of cardiac-valve regurgitation
@en
P2093
Edeltraut Garbe
Frank Andersohn
René Schade
Samy Suissa
P3181
P356
10.1056/NEJMOA062222
P407
P577
2007-01-04T00:00:00Z